向髓氧化酶限制了髓细胞免疫抑制,增强了胰腺癌的免疫检查点治疗
Angisha Basnet1, Kaitlyn M Landreth1, Remi Nohoesu1
1Department of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, 64 Medical Center Drive, Morgantown, WV, 26506, USA.
Cancer immunology, immunotherapy : CII
|February 17, 2024
概括
骨髓氧化酶 (MPO) 在胰腺癌中驱动免疫抑制,阻碍免疫治疗. 在小鼠中抑制MPO通过减少免疫抑制细胞显著改善了对免疫检查点治疗的反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 胰腺管道腺癌对包括免疫检查点治疗在内的疗法表现出极端的耐药性.
- 一个关键因素是免疫抑制瘤微环境,富含免疫抑制髓状细胞.
- 骨髓状细胞通过增加反应性氧物种 (ROS) 生产,在一定程度上促进免疫抑制.
研究的目的:
- 研究骨髓氧化酶 (MPO) 的作用,这是骨髓状细胞中主要的ROS源,在胰腺癌抵抗免疫检查点治疗中的作用.
- 评估MPO抑制与免疫检查点疗法结合的治疗潜力.
主要方法:
- 在野生型,MPO缺陷和MPO抑制剂治疗小鼠中利用临床前皮下胰腺癌模型.
- 评估治疗结果,免疫细胞组成和髓状细胞特征.
- 在孤立的骨髓状细胞子集中分析了ROS的产生和T细胞抑制.
主要成果:
- 联合MPO缺乏或抑制与免疫检查点治疗显著延迟瘤生长.
- 缺少MPO导致瘤微环境和全身免疫场景中的髓状细胞减少,T细胞耗尽,和调节性T细胞.
- 骨髓细胞中MPO的损失降低了ROS的产生和T细胞的抑制.
结论:
- 骨髓氧化酶积极促进免疫抑制瘤微环境,有助于在胰腺癌中抵抗免疫检查点治疗.
- 用抑制剂向MPO是一种有前途的策略,可以提高胰腺癌患者的免疫治疗疗效.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


